Skip to main content
Premium Trial:

Request an Annual Quote

Regeneron, Scandanavian Schools to Study Genetics of Diabetes

NEW YORK (GenomeWeb) – Lund University said last week that it has partnered with the Regeneron Genetics Center (RGC) and the University of Helsinki on a study to investigate the genetics of diabetes.

In the so-called Botnia study, the RCG — a subsidiary of Regeneron Pharmaceuticals — will perform exome sequencing and whole-genome array genotyping of more than 9,000 individuals with diabetes or with diabetic relatives from around 1,400 families in Finland and southern Sweden.

Researchers from the RCG, Lund University, and the University of Helsinki will analyze the data in order to identify genetic mutations linked to different conditions associated with diabetes such as insulin sensitivity. 

"By studying hereditarily transmitted mutations in families, we can understand which causes are genetic and which are environmental, i.e. due to lifestyle," Leif Groop, head of the Lund University Diabetes Centre, said in a statement.

"If we can understand the cause, we can study the molecular mechanism behind the disease, which would enable the development of new drugs to treat it," Nikolay Oskolkov, a researcher at the center, added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.